Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone

Autor: Anastasia Y Ipatova, Pamela H Koerner, Richard T Miller, Francis Staskon, Melanie Radi

Publikováno v: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, Vol 13 (2019)

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease which results in thickening and scarring of the interstitial tissue. As the only 2 Food and Drug Administration (FDA)-approved medications on the market, it is valuable to com

Externí odkaz: https://doaj.org/article/77d3e135787e4ca5b3f06be7ef7f148b

Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database

Autor: Khalid M. Kamal, Z. Mehta, Richard T. Miller, Vincent J. Giannetti, Jordan R. Covvey

Publikováno v: Journal of Drug Assessment
article-version (VoR) Version of Record

Background There have been significant advances in Cystic Fibrosis (CF) treatment, with the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators. Adherence is an important goal for CF management, as nonadherence is li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac02e4a21a251a6ec6730613fa483844
https://doi.org/10.1080/21556660.2021.1912352

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer

Autor: William D. Trombatt, Richard T. Miller, Lakyn Husinka, Pamela H. Koerner

Publikováno v: Journal of Drug Assessment
article-version (VoR) Version of Record

Objective The purpose of this study is to review CDK 4/6 inhibitors used to treat metastatic breast cancer for patient safety, cost and utilization. By evaluating patient outcomes and payer influence, this study will provide critical information to a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9791a6b79b2ad93ceef2d315fe2d6a2
https://pubmed.ncbi.nlm.nih.gov/33414982

Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone

Autor: Melanie Radi, Francis Staskon, Richard T. Miller, Anastasia Y Ipatova, Pamela H. Koerner

Publikováno v: Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, Vol 13 (2019)

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease which results in thickening and scarring of the interstitial tissue. As the only 2 Food and Drug Administration (FDA)-approved medications on the market, it is valuable to com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48de9e6205ab5e4f04b871f322b7746c
http://europepmc.org/articles/PMC6416683

Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy

Autor: Pamela H. Koerner, Melanie Radi, Richard T. Miller, Michael McCall

Publikováno v: Journal of Drug Assessment

Background: Hemophilia A is a genetic bleeding disorder caused by a deficiency in factor VIII (FVIII). FVIII maintains bleeding homeostasis within the body through its downstream effects on the intrinsic clotting cascade. The extent of the disease �

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da37cb8223f1804781ebf7b5b79b521f
https://doi.org/10.1080/21556660.2019.1658327